We are live on
!
Find out more
GA
Geneva Advisors Portfolio holdings
AUM
$5.81B
Turnover
22.5%
1-Year Est. Return
23.71%
This Fund
S&P 500
This Quarter
Est. Return
-6.12%
1 Year Est. Return
+23.71%
3 Year Est. Return
+53.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.96B
AUM Growth
-$641M
(-11%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
23.33%
Holding
765
New
46
Increased
242
Reduced
270
Closed
98
Avg Time Held
1.5
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Manhattan Associates
MANH
|
+$33.6M |
| 2 |
Amazon
AMZN
|
+$32.3M |
| 3 |
CEB
CEB Inc.
CEB
|
+$27.7M |
| 4 |
Gilead Sciences
GILD
|
+$27.3M |
| 5 |
Merck
MRK
|
+$25.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$49.9M |
| 2 |
TWX
Time Warner Inc
TWX
|
+$30.5M |
| 3 |
Stericycle Inc
SRCL
|
+$29.3M |
| 4 |
Macquarie Infrastructure Holdings, LLC
MIC
|
+$25M |
| 5 |
Sunoco
SUN
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.16% |
| 2 | Financials | 16.84% |
| 3 | Consumer Discretionary | 14.26% |
| 4 | Technology | 13.32% |
| 5 | Industrials | 10.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
301
Canadian Pacific Kansas City
CP
$76.4B
| $781K | 0.02% |
27,200
-4,600
| -14% | -$139K |
2013 Q4
7 quarters
|
|
302
Mondelez International
MDLZ
$80.4B
| $781K | 0.02% |
18,647
+1,419
| +8% | +$61.1K |
2013 Q2
9 quarters
|
|
|
BXLT
303
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $772K | 0.02% |
+24,498
| New | +$845K |
2015 Q3
0 quarters
|
|
304
Emerson Electric
EMR
$90.4B
| $727K | 0.01% |
16,467
-3,891
| -19% | -$191K |
2013 Q2
9 quarters
|
|
305
Lowe's Companies
LOW
$110B
| $726K | 0.01% |
10,531
+145
| +1% | +$9.97K |
2013 Q2
9 quarters
|
|
306
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
| $713K | 0.01% |
12,620
-710
| -5% | -$46K |
2013 Q2
9 quarters
|
|
|
ENH.PRA
307
DELISTED
ENDURANCE SPECIALTY HOLDINGS LTD PFD SER A
ENH.PRA
| $704K | 0.01% |
27,700
+4,200
| +18% | +$108K |
2013 Q2
9 quarters
|
|
308
Papa John's
PZZA
$644M
| $681K | 0.01% |
9,950
-10,605
| -52% | -$764K |
2015 Q2
1 quarter
|
|
309
Thermo Fisher Scientific
TMO
$258B
| $671K | 0.01% |
5,486
+3,759
| +218% | +$490K |
2015 Q2
1 quarter
|
|
310
Franco-Nevada
FNV
$46.5B
| $669K | 0.01% |
15,205
-1,650
| -10% | -$71.1K |
2014 Q1
6 quarters
|
|
|
CLA.CL
311
DELISTED
Capitala Finance Corp.
CLA.CL
| $664K | 0.01% |
26,300
+1,000
| +4% | +$25.6K |
2014 Q2
5 quarters
|
|
312
Celanese
CE
$5.1B
| $663K | 0.01% |
11,208
-465
| -4% | -$29.5K |
2013 Q3
8 quarters
|
|
313
Simon Property Group
SPG
$65.8B
| $657K | 0.01% |
3,574
-40
| -1% | -$7.33K |
2013 Q2
9 quarters
|
|
314
Vanguard S&P 500 ETF
VOO
$1.05T
| $649K | 0.01% |
3,696
+1,041
| +39% | +$194K |
2014 Q1
6 quarters
|
|
315
Ingredion
INGR
$6.13B
| $647K | 0.01% |
7,415
-335
| -4% | -$28.7K |
2014 Q1
6 quarters
|
|
316
Northern Trust
NTRS
$30.3B
| $638K | 0.01% |
9,361
+1
| +0% | +$73 |
2013 Q2
9 quarters
|
|
317
Snap-on
SNA
$18.9B
| $634K | 0.01% |
4,203
| – | – |
2015 Q2
1 quarter
|
|
|
XENT
318
DELISTED
Intersect ENT, Inc
XENT
| $630K | 0.01% |
26,935
+10,711
| +66% | +$296K |
2015 Q2
1 quarter
|
|
319
iShares Preferred and Income Securities ETF
PFF
$12.1B
| $616K | 0.01% |
15,962
+95
| +0.6% | +$3.71K |
2013 Q2
9 quarters
|
|
320
Diageo
DEO
$52.3B
| $605K | 0.01% |
5,610
-306
| -5% | -$34K |
2013 Q2
9 quarters
|
|
321
DELISTED
Coterra Energy
CTRA
| $603K | 0.01% |
27,591
-32
| -0.1% | -$819 |
2013 Q2
9 quarters
|
|
|
LLTC
322
DELISTED
Linear Technology Corp
LLTC
| $600K | 0.01% |
+14,875
| New | +$610K |
2015 Q3
0 quarters
|
|
323
Core Laboratories
CLB
$449M
| $598K | 0.01% |
5,990
+2,950
| +97% | +$321K |
2013 Q2
9 quarters
|
|
324
Duke Energy
DUK
$92.7B
| $591K | 0.01% |
8,210
-151
| -2% | -$10.9K |
2013 Q2
9 quarters
|
|
325
ONE Gas
OGS
$4.69B
| $589K | 0.01% |
12,984
-910
| -7% | -$39.9K |
2014 Q1
6 quarters
|
|
Similar funds
CAM
DL
TCM
HCM
AL
AT
Geneva Advisors's Q3 2015 Portfolio in Review
As of Q3 2015, Geneva Advisors held 765 positions worth $4.96B, down 11% from $5.6B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Geneva Advisors withdrew a net $193M in Q3 2015, closing 98 positions and reducing 270 holdings. Its most notable exit was Potash Corp Of Saskatchewan, an estimated $21.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Geneva Advisors opened a new position in Alphabet (Google) Class A worth $15.8M.
- Geneva Advisors's largest Q3 2015 buy was Alphabet (Google) Class A: 496,420 shares worth $15.8M.
- Geneva Advisors added most to Manhattan Associates in Q3 2015, an estimated $33.6M increase.
- Geneva Advisors's biggest Q3 2015 reduction was Biogen, cutting an estimated $49.9M.
- Geneva Advisors fully exited Potash Corp Of Saskatchewan in Q3 2015, selling an estimated $21.6M.
- Geneva Advisors's ten largest holdings make up 23% of its $4.96B portfolio in Q3 2015.
- Geneva Advisors opened 46 new positions and closed 98 in Q3 2015.
- Geneva Advisors's portfolio value fell 11% quarter-over-quarter to $4.96B.
Based on Geneva Advisors's 13F filing for Q3 2015, filed 3 Nov 2015.